Clinical Trial Update: Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Phase 2]

View source ↗

Summary

Open-label Phase 2 pilot study evaluating tolvaptan for efficacy, tolerability, and safety in autosomal dominant polycystic kidney disease. Results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Polycystic Kidney, Autosomal Dominant | Phase 2 | Status: COMPLETED | Results posted: 2017-07-02